SCHEMBL10752879

SCHEMBL10752879

CCCCCOCC(COP(=O)(O)OCCN)OCCCCC

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2C Q5R387 1/20 0.71
▸ LPAR1 Q92633 9/20 0.68
▸ LPAR3 Q9UBY5 9/20 0.68
▸ LPAR2 Q9HBW0 6/20 0.59
▸ PLA2G2D Q9UNK4 1/20 0.52
▸ TLR2 O60603 3/20 0.49
▸ LPAR5 Q9H1C0 6/20 0.47
▸ LPAR6 P43657 5/20 0.47
▸ LPAR4 Q99677 5/20 0.47
▸ P2RY10 O00398 2/20 0.46
▸ AKT1 P31749 2/20 0.45
▸ PLCG2 P16885 1/20 0.45
▸ PIK3R1 P27986 1/20 0.45
▸ AKT2 P31751 1/20 0.45
▸ PIK3CA P42336 1/20 0.45
▸ AKT3 Q9Y243 1/20 0.45
▸ GAB1 Q13480 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL608015 1.00 PLA2G2C (0.71) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL12506212 1.00 PLA2G2C (0.71) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL23300849 0.99 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL21568785 0.99 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL28622692 0.99 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL25394384 0.99 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL931685 0.99 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL22092476 0.99 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL2702607 0.99 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D
SCHEMBL28781558 0.99 PLA2G2C (0.73) PLA2G2CLPAR1LPAR3LPAR2PLA2G2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115504945-A Ionizable heterocyclic lipid molecule and application thereof in preparation of lipid nanoparticles 南京吉迈生物技术有限公司 2022-12-23 — — CN claimed
EP-3397244-B1 TREATMENT OF BREAST CANCER USING A COMBINATION OF A CATIONIC LIPOSOMAL FORMULATION OF TAXANE, A NON-LIPOSOMAL FORMULATION OF TAXANE AND A FURTHER ACTIVE AGENT SYNCORE BIOTECHNOLOGY CO LTD (TW) 2021-10-06 — — EP claimed
CN-114787127-B Ionizable lipids and nanoparticle compositions thereof 世代生物公司 2024-04-26 — — CN disclosed
CN-117241780-A Biological delivery system 帕帝塞拉公司 2023-12-15 — — CN disclosed
CN-116082184-B Ionizable lipid and lipid nanoparticle based on cyclohexanediamine, and preparation method and application thereof 山东大学 2023-06-30 — — CN disclosed
CN-116082184-A Ionizable lipid and lipid nanoparticle based on cyclohexanediamine, and preparation method and application thereof 山东大学 2023-05-09 — — CN disclosed
CN-113908292-B Target-mediated nucleic acid nano preparation and preparation method thereof 南京吉迈生物技术有限公司 2022-08-16 — — CN disclosed
CN-113908292-A Target-mediated nucleic acid nano preparation and preparation method thereof 南京吉迈生物技术有限公司 2022-01-11 — — CN disclosed
US-4687766-A MIXTURE OF OXICAM DERIVATIVES WITH PHOSPHOLIPID A. NATTERMAN & CIE, GMBH (DE) 1987-08-18 — — US disclosed
Send feedback